Sentences with phrase «new targeted cancer therapies»
- A large proportion of new targeted cancer therapies are based on antibodies.
https://www.sciencedaily.com/ Not exact matches
But he adds that the industry has entered a new cycle where targeted therapies, particularly in cancer treatments, means there are some good returns on R&D.
Cambridge, MA — February 6, 2017 — Aura Biosciences, a biotechnology company developing a new class of therapies to target and selectively destroy cancer cells using viral nanoparticle conjugates, announced today that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug application (IND) for the company's lead program, light - activated AU - 011 in ocular melanoma (OM).
Cambridge, MA — December 21, 2017 — Aura Biosciences, a biotechnology company developing a new class of therapies to target and selectively destroy cancer cells using viral nanoparticle conjugates, announced today that it closed a $ 30 million Series C financing.
Cambridge, MA — March 30, 2017 — Aura Biosciences, a biotechnology company developing a new class of therapies to target and selectively destroy cancer cells using viral nanoparticle conjugates, announced today that it has enrolled and dosed the first patient in its Phase 1b clinical trial of light - activated AU - 011, an investigational, first - in - class targeted therapy in development for the treatment of ocular melanoma, a rare and life - threatening disease.
Its first indication is a rare cancer that affects only 3,100 new patients each year, and the drug only targets roughly 30 % of those patients who do not respond to standard therapy.
«These new drugs are opening the door for more avenues of targeted therapy for the future,» says American Cancer Society president Ralph Vance, a professor of medicine at the University of Mississippi School of Medicine.
Scientists at Lawson Health Research Institute have uncovered an important new target for ovarian cancer therapy.
He hopes that further studies may identify novel approaches to immune - based cancer therapy or reveal new drug targets for inflammatory diseases.
«It is expected that this study will lay the foundation for developing a new class of potent and effective cancer therapies and the development of reagents targeting epigenetic events in immune - mediated diseases as well as other epigenetically - influenced diseases,» said Alani, who also is chief of dermatology at Boston Medical Center.
A new wave of potential immune therapies aims to target the network of complex sugars that coat cancer cells, Esther Landhuis reported in «Cancer's sweet cloak» (SN: 4/1/17, pcancer cells, Esther Landhuis reported in «Cancer's sweet cloak» (SN: 4/1/17, pCancer's sweet cloak» (SN: 4/1/17, p. 24).
My cancer systems biology team at the University of California, Merced, is tackling diagnosis and treatment of therapy - resistant cancers by elucidating the network of changes within cells as a way to identify new drug targets and circumvent cancer resistance.
These results not only show promise on a new targeted therapy to treat this malignancy, as PI3K inhibitors are already used in the clinical practice, but also unravel a new function of the PI3K kinase in cancer biology through its role in promoting metastasis.
This is important because it makes it possible to model almost any autoimmune disease, evaluate new drug therapies, and even identify novel targets in the emerging area of cancer immunotherapies.
«This is a seminal step in identifying key pathways and molecules involved in kidney cancer so that specific therapies that target these new genes can be developed to treat this cancer.»
«Thanks to a deeper understanding of cancer biology, we have a potential new targeted therapy for multiple myeloma, and can better tailor treatment for kids with Wilms tumor.
«This brings these members of the epothilone class within range of suitability as payloads for antibody - drug conjugates, a new paradigm for targeted cancer therapy.»
An international study involving Manchester researchers has found that for previously untreated lung cancer patients with a particular genetic change, a new targeted therapy is better than standard chemotherapy.
In cases of new infection, prompt and targeted therapy is vital, as it can prevent the disease developing into a chronic condition that can lead to inoperable liver cancer.
«By helping us understand that lower levels of RNF125 confer resistance to BRAF inhibitors, we have a new strategy to stratify patients for currently approved therapy versus participation for human clinical trials to investigate whether targeting JAK1 will be more effective in patients whose tumors exhibit reduced RNF125,» said Keith T. Flaherty, M.D., associate professor, Harvard Medical School, and director of Developmental Therapeutics, Cancer Center, Massachusetts General Hospital, and co-author of the study.
«The good news is that this finding predicts that patients missing either gene should be sensitive to new therapies targeting focal adhesion enzymes, which are currently being tested in early - stage clinical trials,» says Shaw, who is also a member of the Moores Cancer Center and an adjunct professor at the University of California, San Diego.
For patients, down the road Dr. Ohashi envisions a new era of combined therapies to simultaneously target and kill these suppressive cells while augmenting the immune response against cancer.
«Multiple epigenetic regulators participate in the drug - desensitizing pathway, so they could serve as new targets to improve therapy for this type of cancer.»
New research from The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai identifies a protein that may be an unexplored target to develop new cancer therapiNew research from The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai identifies a protein that may be an unexplored target to develop new cancer therCancer Institute at the Icahn School of Medicine at Mount Sinai identifies a protein that may be an unexplored target to develop new cancer therapinew cancer thercancer therapies.
«Cancer cell metabolism kills: Possible new therapies targeting energy supply of cancer cells?.&Cancer cell metabolism kills: Possible new therapies targeting energy supply of cancer cells?.&cancer cells?.»
«One of the challenges of current cancer therapies, including new targeted therapies, is a cancer cell's ability to overcome a treatment's anticancer properties.
These findings may lead to new therapies specifically targeting the altered energy supply chains of cancer cells to get cancer cells to commit suicide.
The findings, which were published online in the journal Cancer Cell, could ultimately lead to new targeted therapies for many other types of cancer carrying similar p53 mutaCancer Cell, could ultimately lead to new targeted therapies for many other types of cancer carrying similar p53 mutacancer carrying similar p53 mutations.
Nevertheless, trying to develop new therapies based on what treatments will look like in the coming decade is a nearly impossible task, points out Michael Stratton, joint head of the Cancer Genome Project and professor of cancer genetics at the University of London's Institute of Cancer Research, who has been working on developing finely targeted cancer treatments since identifying the BRAF oncogene inCancer Genome Project and professor of cancer genetics at the University of London's Institute of Cancer Research, who has been working on developing finely targeted cancer treatments since identifying the BRAF oncogene incancer genetics at the University of London's Institute of Cancer Research, who has been working on developing finely targeted cancer treatments since identifying the BRAF oncogene inCancer Research, who has been working on developing finely targeted cancer treatments since identifying the BRAF oncogene incancer treatments since identifying the BRAF oncogene in 2002.
The formation of new blood vessels, called angiogenesis, is therefore a possible target for cancer therapy.
The discovery sheds new light on the origin of this deadly cancer, suggesting that therapies have largely failed because they are aimed at the wrong target.
Given Rac1 suppresses this inflammation, it may be a new target for cancer therapies.
Their findings could help to improve breast cancer prevention by targeting these specific biological mechanisms with cancer therapies in at risk patients and potentially lead the way for a new strategy for the use of preventative treatments.
Research from Rutgers Cancer Institute of New Jersey examining difficult to treat cancer tumors through genomic profiling shows that tumors with alterations in a signaling pathway responsible for cell regulation may respond to targeted therapy regardless of where the tumor originated in theCancer Institute of New Jersey examining difficult to treat cancer tumors through genomic profiling shows that tumors with alterations in a signaling pathway responsible for cell regulation may respond to targeted therapy regardless of where the tumor originated in thecancer tumors through genomic profiling shows that tumors with alterations in a signaling pathway responsible for cell regulation may respond to targeted therapy regardless of where the tumor originated in the body.
Research from Rutgers Cancer Institute of New Jersey examining gynecologic cancers that poorly respond to therapy shows genomic profiling can help identify alternate and targeted treatments.
This new knowledge is also making precision medicine a reality by enabling the development of highly targeted therapies that offer the potential for improved treatment outcomes, especially for patients battling cancer.
The researchers say these new findings predict that a large proportion of Pten tumors will be hypersensitive to Eg5 - inhibiting drugs, providing new opportunities for targeted cancer therapy.
«Targeting a number of these genes simultaneously might be a potent new broad - spectrum therapy for cancer.»
«New chemical technology boosts potency of targeted cancer therapy.»
The enzyme has recently been found in many human tumors and is being eyed as a new target for cancer therapy
In the era of personalized cancer therapy, patients with TNBC remain at considerably higher risk of relapse and death than patients with other breast cancer subtypes, due to the aggressive nature of TNBC and the lack of newer targeted therapies for the disease.
New studies from the Abramson Cancer Center of the University of Pennsylvania are providing fresh clues on potentially effective combinations with CAR T therapy in brain cancer as well as a novel therapeutic target in head and neck cancer, and also providing greater understanding of the mechanisms of resistance in pancreatic cCancer Center of the University of Pennsylvania are providing fresh clues on potentially effective combinations with CAR T therapy in brain cancer as well as a novel therapeutic target in head and neck cancer, and also providing greater understanding of the mechanisms of resistance in pancreatic ccancer as well as a novel therapeutic target in head and neck cancer, and also providing greater understanding of the mechanisms of resistance in pancreatic ccancer, and also providing greater understanding of the mechanisms of resistance in pancreatic cancercancer.
«Going to «Wars» against cancer, heart disease: Uncovered gene may provide target for new therapies.»
«Capturing the Spectrum of Hereditary Cancers: A Moving Target in the Setting of Targeted Therapy» Hetal Vig, MS Assistant Professor of Medicine Rutgers Robert Wood Johnson Medical School Board Certified Genetic Counselor Rutgers Cancer Institute of New Jersey
One of these, called FADD, has previously been linked to head and neck cancer and lung cancer and could be a promising target for new cancer therapies.
Hu Y, Fu L. Targeting cancer stem cells: a new therapy to cure cancer patients.
University of California San Francisco researchers may have discovered why the experimental anti-cancer drug Onyx - 015 works more broadly than had been expected, a finding that could solidify and expand use of the drug and which reveals a potential new target for therapy that could prompt the development of other cancer drugs.
LA JOLLA — Scientists at the Salk Institute for Biological Studies have identified a key genetic switch linked to the development, progression and outcome of cancer, a finding that may lead to new targets for cancer therapies.
As MD Anderson moves toward molecular characterization of the cancers of all our patients, allowing their optimal assignments to promising new targeted therapies and potential identification of biomarkers of response and resistance, the department's mission includes thematic translational research and preclinical molecular pathology research.
In the last several years, her lab has been motivated to study a class of enzymes called TUTases, which are promising targets for new cancer therapies.